The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

The agency announced that after concerns were raised about levels of benzene in products containing benzoyl peroxide, they ...

A popular over-the-counter (OTC) acne treatment sold at Walgreens and other U.S. retailers is being recalled because it was ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

The T1 results showed that Roche’s drug reduced the total number of new ... with forecasted sales of approximately $2.6 billion across seven of the largest pharma markets.

Gantenerumab shows promise in preventing Alzheimers disease after past failures Gantenerumab demonstrates significant ...

ZURICH, March 19 (Reuters) - Swiss drugmaker Roche has abandoned global diverse ... race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters ...

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer ... of efficacy in a first-line NSCLC study. With the SKYSCAPER-6 result now in, Roche said it will “evaluate any relevant changes ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...